BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

...used on smartphones and other mobile devices. Medimetriks planning U.S. Phase III in atopic dermatitis Medimetriks Pharmaceuticals Inc....
...atopic dermatitis patients. The PDE-4 inhibitor decreased the severity of systemic symptoms compared with vehicle. Medimetriks...
...kinase LpxC - Bacterial UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase PDE-4 - Phosphodiesterase-4 Hongjiang Li, Staff Writer tepotinib (MSC2156119J) JZP-258 Pear Therapeutics Inc. Medimetriks Pharmaceuticals Inc. Otsuka...
BioCentury | Jul 31, 2018
Company News

Management tracks: Canbridge, Retrophin

...Rare disease company Retrophin Inc. (NASDAQ:RTRX) hired Noah Rosenberg as CMO. He was CMO at Medimetriks Pharmaceuticals Inc....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Nov 10, 2017
Clinical News

Medimetriks reports Phase II data for MM36 in atopic dermatitis

...In September, Medimetriks Pharmaceuticals Inc. (Fairfield, N.J.) reported data from the Phase II MUSE trial in 32 patients...
...include safety, time to itch relief, change in sleep patterns and improvement in disease severity. Medimetriks...
...pivotal trial in 1Q18, and hopes to submit an NDA for the compound in 2H19. Medimetriks...
BioCentury | Sep 5, 2016
Clinical News

Ozenoxacin 1% regulatory update

...FDA accepted for review an NDA from Medimetriks for ozenoxacin 1% cream to treat impetigo. The...
...non-fluorinated quinolone antibacterial that inhibits DNA gyrase and topoisomerase IV . In 2014, Ferrer granted Medimetriks...
...worldwide rights to the product outside of China, Japan, Korea and Taiwan from Toyama Chemical. Medimetriks Pharmaceuticals Inc....
BioCentury | Jul 11, 2016
Clinical News

Ozenoxacin 1% regulatory update

...an NDA to FDA for ozenoxacin 1% cream to treat impetigo. In 2014, Ferrer granted Medimetriks...
BioCentury | Feb 15, 2016
Company News

Otsuka Pharmaceutical, Medimetriks deal

...Otsuka granted Medimetriks exclusive rights to develop and commercialize OPA-15406 in the U.S. The phosphodiesterase-4 (PDE-4...
...The companies declined to provide further financial terms. Otsuka Pharmaceutical Co. Ltd. , Tokyo, Japan Medimetriks Pharmaceuticals Inc....
BioCentury | Aug 3, 2015
Clinical News

Ozenoxacin 1%: Phase III data

...worldwide rights to ozenoxacin 1% outside of China, Japan, Korea and Taiwan from Toyama Chemical. Medimetriks Pharmaceuticals Inc....
...1% and Cipher Pharmaceuticals Inc. (TSX:CPH; NASDAQ:CPHR, Mississauga, Ontario) has exclusive commercialization rights in Canada. Medimetriks...
BioCentury | Dec 11, 2014
Targets & Mechanisms

Lysin in wait

...Staphefekt developed resistance to the antibiotic but not to Staphefekt. 2 Centany is marketed by Medimetriks Pharmaceuticals Inc....
...Yonkers, N.Y. Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Medimetriks Pharmaceuticals Inc....
BioCentury | Jun 23, 2014
Clinical News

Ozenoxacin 1%: Phase III started

...worldwide rights to the product outside of China, Japan, Korea and Taiwan from Toyama Chemical. Medimetriks Pharmaceuticals Inc....
Items per page:
1 - 10 of 12
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

...used on smartphones and other mobile devices. Medimetriks planning U.S. Phase III in atopic dermatitis Medimetriks Pharmaceuticals Inc....
...atopic dermatitis patients. The PDE-4 inhibitor decreased the severity of systemic symptoms compared with vehicle. Medimetriks...
...kinase LpxC - Bacterial UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase PDE-4 - Phosphodiesterase-4 Hongjiang Li, Staff Writer tepotinib (MSC2156119J) JZP-258 Pear Therapeutics Inc. Medimetriks Pharmaceuticals Inc. Otsuka...
BioCentury | Jul 31, 2018
Company News

Management tracks: Canbridge, Retrophin

...Rare disease company Retrophin Inc. (NASDAQ:RTRX) hired Noah Rosenberg as CMO. He was CMO at Medimetriks Pharmaceuticals Inc....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Nov 10, 2017
Clinical News

Medimetriks reports Phase II data for MM36 in atopic dermatitis

...In September, Medimetriks Pharmaceuticals Inc. (Fairfield, N.J.) reported data from the Phase II MUSE trial in 32 patients...
...include safety, time to itch relief, change in sleep patterns and improvement in disease severity. Medimetriks...
...pivotal trial in 1Q18, and hopes to submit an NDA for the compound in 2H19. Medimetriks...
BioCentury | Sep 5, 2016
Clinical News

Ozenoxacin 1% regulatory update

...FDA accepted for review an NDA from Medimetriks for ozenoxacin 1% cream to treat impetigo. The...
...non-fluorinated quinolone antibacterial that inhibits DNA gyrase and topoisomerase IV . In 2014, Ferrer granted Medimetriks...
...worldwide rights to the product outside of China, Japan, Korea and Taiwan from Toyama Chemical. Medimetriks Pharmaceuticals Inc....
BioCentury | Jul 11, 2016
Clinical News

Ozenoxacin 1% regulatory update

...an NDA to FDA for ozenoxacin 1% cream to treat impetigo. In 2014, Ferrer granted Medimetriks...
BioCentury | Feb 15, 2016
Company News

Otsuka Pharmaceutical, Medimetriks deal

...Otsuka granted Medimetriks exclusive rights to develop and commercialize OPA-15406 in the U.S. The phosphodiesterase-4 (PDE-4...
...The companies declined to provide further financial terms. Otsuka Pharmaceutical Co. Ltd. , Tokyo, Japan Medimetriks Pharmaceuticals Inc....
BioCentury | Aug 3, 2015
Clinical News

Ozenoxacin 1%: Phase III data

...worldwide rights to ozenoxacin 1% outside of China, Japan, Korea and Taiwan from Toyama Chemical. Medimetriks Pharmaceuticals Inc....
...1% and Cipher Pharmaceuticals Inc. (TSX:CPH; NASDAQ:CPHR, Mississauga, Ontario) has exclusive commercialization rights in Canada. Medimetriks...
BioCentury | Dec 11, 2014
Targets & Mechanisms

Lysin in wait

...Staphefekt developed resistance to the antibiotic but not to Staphefekt. 2 Centany is marketed by Medimetriks Pharmaceuticals Inc....
...Yonkers, N.Y. Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Medimetriks Pharmaceuticals Inc....
BioCentury | Jun 23, 2014
Clinical News

Ozenoxacin 1%: Phase III started

...worldwide rights to the product outside of China, Japan, Korea and Taiwan from Toyama Chemical. Medimetriks Pharmaceuticals Inc....
Items per page:
1 - 10 of 12